The Clinical R Esearch Into Gastrodin Sustained- Release Tablets And Escitalopram Oxalate Tablets On Patients With Poststroke Depression

Objective From the study,through the observation of Gastrodin Sustained-release Tablets and Escitalopram Oxalate Tablets on Patients who with Poststroke depression with depression symptoms, the quality of asleep 、the quality of life and medication adverse reaction, to evaluate gastrodin sustained-release tablets in the treatment of PSD in safety and efficacy. By detecting Peripheral Blood before and after treatment in patients with insulin-like growth factor 1(IGF-1)and Brain derived neurotrophic factor(BDNF). Compare the differences in symptom improvement. In order to discuss the etiology and pathogenesis of the Poststroke depression may gastrodin sustained-release tablets on PSD treatment and symptom improvement possible mechanisms, in order to further provide the theoretical basis of clinical research and medication,and Combine traditional Chinese and western medicine treatment of poststroke depression provide a new research direction.Methods Select 64 cases as research object treated from may to October2014 in Neural Department of internal medicine ward of wuhanGeneral Hospital of Guangzhou military command, all patients Volunteered for the study. All cases have been divided into two groups, the observation group which is gastrodin sustained-release tablets group(sustained release tablets group as short) have 32 cases, controlled group 32 cases.All patients have no statistically significant differences(p>0.05)in the general clinical information such as age, gender,NIHSS,etc.the Observation group was given gastrodin sustained-release tablets(developed by clinical pharmacology of Wuhan General Hospital of Guangzhou military region)150mg-oral 1 tablet once 2 tablets/day(total 300mg),and Escitalopram Oxalate Tablets 10mg-oral 1 tablet once 1 tablets/day(total10mg);the controlled group is only given Escitalopram Oxalate Tablets of 10mg-oral 1 tablet once 1 tablets/day(total10mg), Evaluation respectively before and at the end of 5 weeks changes in patients with Hamilton depression scale(HAMD), Pittsburgh sleep quality index scale(PSQI) and the concentration of serum brain derived neurotrophic(IGF–1).in order to Explore gastrodine zyban with escitalopram oxalate citalopram for efficacy and safety of poststroke depression(ischemic) characteristics.Results ①Gastrodin Sustained-release Tablets and Escitalopram Oxalate Tablets is more significantly(P < 0.01)than Escitalopram Oxalate Tablets in improving the effect of depression after stroke, especially to improve sleep quality, anxiety/somatization and despair effects.what is more, the Observation group has improve the quality of patients with sleep than control group in PSQI scores(P < 0.05), of which is more significantin improve the sleep time, sleep efficiency, daytime function, and the sleep barrier effect than the control group(escitalopram oxalate citalopram), effectively improve the quality of life of patients who is poststroke depression. ② On the one hand, Compared the BDNF concentration before and after the test, we found that in the control group(escitalopram oxalate citalopram group) and the observation group(gastrodia elata zyban joint escitalopram oxalate citalopram) can improve the level of serum BDNF after ischemic stroke patients of depression,but the observation group improve the role of BDNF levels more significant(P<0.01);on the other hand, On the one hand,Compared the IGF-1 concentration before and after the test, we found that in the control group(escitalopram oxalate citalopram group) and the observation group(gastrodia elata zyban joint escitalopram oxalate citalopram) can reduce the level of serum BDNF after ischemic stroke patients of depression,but the observation group reduce the role of IGF-1levels more significant(P<0.01)so we could concluded gastrodine may increase the content of BDNF in the brain, reduce the level of IGF-1, so as to conducive the growth of neurons, differentiation, maturation and neural plasticity, protect nerve cells.indirectly, enhance the level of single amine neurotransmitter in the brain,and play a key role inantidepressant. ③ The safety indexs such as routine blood, liver and kidney function, body weight have no obvious abnormalities before and after medication, it explain gastrodine joint escitalopram oxalate citalopram is security in clinical application,and gastrodine zyban medication is convenient, improve depression and sleep disturbance,improve the quality of life and work efficiency in patients with PSDConclusion ① Gastrodine zyban joint escitalopram oxalate citalopram in improving depression also is significant.,at the same time, its effect in improving sleep quality.②Gastrodia elata zyban joint escitalopram oxalate citalopram can improve the level of BDNF in plasma, and reduce the concentration of IGF- 1.it help the growth differentiation, maturation and neural plasticity, indirectly, enhance the level of single amine neurotransmitter in the brain,play a role in antidepressant.③There is one case of adverse clinical response(severe gastrointestinal symptoms such as anorexia, nausea, vomiting), but did not explicitly exclude whether its adverse reactions associated with other drugs at the same time.Gastrodia elata zyban joint escitalopram oxalate citalopram treatment of poststroke depression is safety, effective and not gain weight, In the process of taking the medicine,it is no obvious adverse reaction occurred...